Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 593 publications.
Skip to main content
Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster presented at the ISPOR 2025; May 16, 2025. Montréal, Canada.
La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster presented at the ISPOR 2025; May 13, 2025. Montréal, Canada.
George S, Carrico J, Hicks KA, Loukov D, Ng C, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada. BMC Health Serv Res. 2025 Apr 25;25(1):604. doi: 10.1186/s12913-025-12550-x
Wilson MR, Castaman G, Thomas W, Millar CM, Escolar G, Miesbach WA, McDade CL, Tomic R, Yan S. Cost-effectiveness of voncento prophylaxis versus on-demand treatment in von willebrand disease in the United Kingdom. Blood Adv. 2025 Mar 25;9(6):1312-9. doi: 10.1182/bloodadvances.2024014376
Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.
Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.
Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Grace M, Khan SA, Kuylen E, Begum S, Verelst F, Kocaata Z. Market and non-market productivity losses associated with invasive meningococcal disease in the USA. Pharmacoeconomics. 2025 Mar 12. doi: 10.1007/s40273-025-01477-0
Megias-Vericat JE, Escolar G, Wilson MR, Mendez P, McDade CL, Barrientos LV, Tomic R, Panebianco M, Linden S, Yan S. Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain. J Med Econ. 2025 Mar 7;28(1):436-45. doi: 10.1080/13696998.2025.2474886
Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Hicks KA, Carrico J, Grace M, Clements DE, Burman C, Sohn WY, Kuylen E, Begum S, Kocaata Z. Public health impact of introducing a pentavalent vaccine against invasive meningococcal disease in the United States. Pharmacoeconomics. 2025 Mar;43(3):311-29. doi: 10.1007/s40273-024-01439-y
Viguerie A, O'Shea J, Johnston M, Schreiber D, Adams J, Bates L, Carrico J, Hicks KA, Lyles CM, Farnham PG. Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines. AIDS. 2025 Feb 5. doi: 10.1097/QAD.0000000000004144
Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.619
Barbieri M, Talbird S, Carrico J, Boccalini S, Bencina G, Bonanni P, Mellott CE, Senese F, Lang JC, Bechini A. Public health impact and return on investment of the pediatric National Immunization Program in Italy. Expert Rev Vaccines. 2024 Dec;23(1):974-85. doi: 10.1080/14760584.2024.2411425
Johannesen K, Herring WL, Chopra R, Elpers B, Dong O. Using patient-level simulation to estimate long-term survival in idiopathic pulmonary fibrosis. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S459-60. doi: 10.1016/j.jval.2024.10.2345
Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States. J Med Econ. 2024 Dec;27(1):758-65. doi: 10.1080/13696998.2024.2351762
Ronquest N, Zhang Y, Paret K, Armstrong S, Mostovoy L, Berggren R. Identifying the value drivers in obesity treatment: a targeted review of weight loss effects on health economic outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S148. doi: 10.1016/j.jval.2024.10.752
Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S43. doi: 10.1016/j.jval.2024.10.228
Hicks KA, Ghaswalla P, Carrico J, Anderson S, Novy P, Hogea C, Hayney MS. Estimating the cost of university-based outbreaks of serogroup B meningococcal disease with different pre-matriculation vaccination policies in the United States. J Am Coll Health. 2024 Nov 21;72(9):3439-48. doi: 10.1080/07448481.2022.2163854
Adelakun A, Dolph M, Matthews E, Oglebsy A, Campbell K, Davis A, Xu J, Hardy I, Danchenko N, Anderson SJ. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Poster presented at the HIV Drug Therapy Glasgow 2024; November 10, 2024. Glasgow, Scotland. [abstract] J Int AIDS Soc. 2024 Nov; 27:234-5.
Carrico J, Talbird SE, Eiden A, Carias C, Huang M, Lang JC, Marshall GS, Bencina G. Direct impact of pediatric immunization on reduction in antibiotic prescribing in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.
Anderson SA, Bian B, Talbird SE, Stratton M, Maxwell R, Ferries R. Medical cost and healthcare resource utilization offset for zuranolone relative to SSRIs in the treatment of postpartum depression. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.
Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. Public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of CMV and congenital CMV in the United States. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, The Netherlands. Previously presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024.
Carrico J, Hicks KA, Wilson E, Panozzo CA, Ghaswalla P. The annual economic burden of respiratory syncytial virus in adults in the United States. J Infect Dis. 2024 Aug 16;230(2):e342-52. doi: 10.1093/infdis/jiad559
Wu B, He X, Tang Z, Martin A, Bracher M, Guo N, Campbell K. Cost-effectiveness analysis of belimumab for the treatment of adults with active lupus nephritis in China. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S77. doi: 10.1016/j.jval.2024.03.405
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.
Dong OM, Herring W, Chopra P, Elpers B, Johannesen K. A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S148. doi: 10.1016/j.jval.2024.03.2259
Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236
O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580
Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9
Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. The public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Germany.
Cook C, Carrico J, Talbird S, Gountas I, Skroumpelos A, Boutselakou E, Trimis G, Sabale U, Bencina G. Public health and economic impact of pediatric immunization program in Greece. Presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Denmark.
Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Real-world impact of pneumococcal conjugate vaccines on invasive pneumococcal disease for serotypes missing prespecified efficacy threshold in immunogenicity trials. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Shah HA, Herrera-Restrepo O, Jutlla G, Carrico J, Hicks K, Kuylen E, Begum S, Clements D, Burman C, Sohn WY, Kocaata Z. Public health impact of MENABCWY vaccination in adolescents and MENB vaccination in infants in the United States. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Shah HA, Herrera-Restrepo O, Jutlla G, Grace M, Graham J, Khan SA, Begum S, Kocaata K. Market and non-market productivity losses associated with invasive meningococcal disease (IMD) in the United States (US). Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Golan Y, Amin AN, Wilson M, Nguyen D, Kvasz M. Clinical and economic outcomes of microbiome therapy for preventing recurrence in recurrent clostridioides difficile infection (Cdi) in the us: comparison of fecal microbiota spores, live-brpk (formerly Ser-109) Vs fecal microbiota, live-Jslm. Poster presented at the Digestive Disease Week (DDW) 2024; May 18, 2024. Washington, DC.
La E, Singer D, Graham J, Grace M, Molnar D. Modeled public health impact of increasing respiratory syncytial virus vaccination coverage among adults Aged ≥ 60 years in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.
George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w
Hohmann C, Manga N, Wolowacz S, Bregantini D, Pfister R. Impact of bempedoic acid on CV outcomes and costs in Germany. Poster presented at the 130th Congress of the German Society of Internal Medicine; April 13, 2024. Wiesbaden, Germany.
Brodtkorb TH, Knight C, Kamgar F, Teitsson S, Kurt M, Patel MY, Poretta T, Mamtani R, Palmer S. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective1. J Med Econ. 2024 Apr 4;27(1):543-53. doi: 10.1080/13696998.2024.2329019
Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Apr;13(4):827-44. doi: 10.1007/s40121-024-00939-w
Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61. doi: 10.1007/s40273-023-01342-y